Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Deffered Revenue (2016 - 2021)

Syndax Pharmaceuticals (SNDX) has 7 years of Non-Current Deffered Revenue data on record, last reported at $10.9 million in Q2 2021.

  • For Q2 2021, Non-Current Deffered Revenue fell 12.25% year-over-year to $10.9 million; the TTM value through Jun 2021 reached $10.9 million, down 12.25%, while the annual FY2020 figure was $11.6 million, 11.54% down from the prior year.
  • Non-Current Deffered Revenue reached $10.9 million in Q2 2021 per SNDX's latest filing, down from $11.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $16.8 million in Q4 2017 and bottomed at $10.9 million in Q2 2021.
  • Average Non-Current Deffered Revenue over 5 years is $13.6 million, with a median of $13.6 million recorded in 2017.
  • Peak YoY movement for Non-Current Deffered Revenue: increased 17.86% in 2017, then decreased 12.58% in 2018.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $16.8 million in 2017, then fell by 12.58% to $14.6 million in 2018, then dropped by 10.35% to $13.1 million in 2019, then decreased by 11.54% to $11.6 million in 2020, then decreased by 6.52% to $10.9 million in 2021.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $10.9 million in Q2 2021, $11.2 million in Q1 2021, and $11.6 million in Q4 2020.